299 related articles for article (PubMed ID: 33665165)
1. Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Bou Zerdan M; Ibrahim M; Nakib CE; Hajjar R; Assi HI
Front Oncol; 2020; 10():609100. PubMed ID: 33665165
[TBL] [Abstract][Full Text] [Related]
2. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.
Blanchette P; Sivajohanathan D; Bartlett J; Eisen A; Feilotter H; Pezo R; Turashvili G; Williams P
Curr Oncol; 2022 Apr; 29(4):2599-2615. PubMed ID: 35448187
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum: Genomic Assays in Node Positive Breast Cancer Patients: A Review.
Bou Zerdan M; Ibrahim M; El Nakib C; Hajjar R; Assi HI
Front Oncol; 2021; 11():686355. PubMed ID: 33937090
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of multigene profiling assays in early-stage breast cancer.
Chang MC; Souter LH; Kamel-Reid S; Rutherford M; Bedard P; Trudeau M; Hart J; Eisen A;
Curr Oncol; 2017 Oct; 24(5):e403-e422. PubMed ID: 29089811
[TBL] [Abstract][Full Text] [Related]
7. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer.
Pauls M; Chia S
Curr Oncol; 2022 Jul; 29(7):5139-5149. PubMed ID: 35877267
[TBL] [Abstract][Full Text] [Related]
9. A narrative review of five multigenetic assays in breast cancer.
Zeng C; Zhang J
Transl Cancer Res; 2022 Apr; 11(4):897-907. PubMed ID: 35571670
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
Andre F; Ismaila N; Allison KH; Barlow WE; Collyar DE; Damodaran S; Henry NL; Jhaveri K; Kalinsky K; Kuderer NM; Litvak A; Mayer EL; Pusztai L; Raab R; Wolff AC; Stearns V
J Clin Oncol; 2022 Jun; 40(16):1816-1837. PubMed ID: 35439025
[TBL] [Abstract][Full Text] [Related]
11. Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands.
de Jongh FE; Efe R; Herrmann KH; Spoorendonk JA
Int J Breast Cancer; 2022; 2022():5909724. PubMed ID: 36250028
[TBL] [Abstract][Full Text] [Related]
12. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on the utility of the Oncotype DX
Siow ZR; De Boer RH; Lindeman GJ; Mann GB
Int J Womens Health; 2018; 10():89-100. PubMed ID: 29503586
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling for breast cancer: a comprehensive review.
Kittaneh M; Montero AJ; Glück S
Biomark Cancer; 2013 Oct; 5():61-70. PubMed ID: 24250234
[TBL] [Abstract][Full Text] [Related]
15. Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany.
Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Herrmann KH; Radeck-Knorre S; Neubauer AS
Cancer Treat Res Commun; 2022; 31():100519. PubMed ID: 35093682
[TBL] [Abstract][Full Text] [Related]
16. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Li H; Zhu Y; Burnside ES; Drukker K; Hoadley KA; Fan C; Conzen SD; Whitman GJ; Sutton EJ; Net JM; Ganott M; Huang E; Morris EA; Perou CM; Ji Y; Giger ML
Radiology; 2016 Nov; 281(2):382-391. PubMed ID: 27144536
[TBL] [Abstract][Full Text] [Related]
17. Gene Expression Assay in the Management of Early Breast Cancer.
Caputo R; Cianniello D; Giordano A; Piezzo M; Riemma M; Trovò M; Berretta M; De Laurentiis M
Curr Med Chem; 2020; 27(17):2826-2839. PubMed ID: 31804159
[TBL] [Abstract][Full Text] [Related]
18. The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer.
Chen K; Wu J; Fang Z; Shao X; Wang X
Technol Cancer Res Treat; 2022; 21():15330338221117402. PubMed ID: 36976899
[TBL] [Abstract][Full Text] [Related]
19. The multigene classifiers 95GC/42GC/155GC for precision medicine in ER-positive HER2-negative early breast cancer.
Naoi Y; Tsunashima R; Shimazu K; Noguchi S
Cancer Sci; 2021 Apr; 112(4):1369-1375. PubMed ID: 33544932
[TBL] [Abstract][Full Text] [Related]
20. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
